On 27 September 2024, the Rwanda Ministry of Health announced the confirmation of Marburg virus disease (MVD). Blood samples taken from people showing symptoms were tested by real-time reverse transcription polymerase chain reaction (RT-PCR) at the National Reference Laboratory of the Rwanda Biomedi...cal Center and were positive for Marburg virus. As of 29 September 2024, a total of 26 confirmed cases, including eight deaths have been reported. The cases are reported from seven of the 30 districts in the country. Among the confirmed cases, over 70% are healthcare workers from two health facilities in Kigali.
more
Please find here the latest Update on MVD in Rwanda
The Global Action Plan on Antimicrobial Resistance (AMR) calls for making AMR a core component of professional education and training. In 2018, the World Health Organization (WHO) published Competency framework for health workers’ education and training on AMR to ensure that academic institutions ...and regulatory agencies provided pre-service and in-service training to equip health workers with the adequate competencies to address AMR. This was followed by Health workers’ training and education on AMR: curricula guide, which outlines the learning objectives and expected outcomes of pre-service training of health workers to improve curricula. These tools were designed to strengthen the capacity of health workers in various settings to address the growing challenge of AMR.
more
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. ...All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
more
Le 14 août, l’Organisation mondiale de la Santé (OMS) déclarait que l’épidémie de variole simienne, dite Mpox, était une « urgence sanitaire internationale », après une flambée des cas en Afrique. Le lendemain, un cas était déclaré en Suède. La branche européenne de l’OMS estime... que d’autres cas importés de Mpox sont susceptibles d’être détectés prochainement en Europe. Ce qu’il faut savoir sur cette épidémie.
more
The safety of children is a top concern for parents and school authorities in the current mpox outbreak, as those
under 15 face elevated risks, particularly in the hardesthit Northwestern and Eastern regions of the Democratic Republic of the Congo.
The report provides an update on the cholera outbreak in Haiti as of January and February 2024. A total of 79,411 suspected cases have been reported, with 4,608 confirmed cases and 1,172 deaths across all 10 departments. The most affected regions include Ouest, Centre, Artibonite, and Nord, with chi...ldren aged 1-9 being the most impacted. Despite a recent decline in reported cases, underreporting due to security issues remains a concern. Response efforts include coordination meetings, epidemiological surveillance, case management, WASH interventions, vaccination campaigns, and community engagement. However, logistical challenges, insecurity, and funding shortages are hindering effective response efforts.
more
On 27 September 2024, the Ministry of Health of Rwanda confirmed the country’s first outbreak of Marburg virus disease (MVD), with health-care workers in Kigali particularly affected. While sporadic outbreaks have occurred in various parts of Africa since the first recognized cases in 1967, this o...utbreak is the third largest outbreak of MVD ever recorded to date. Marburg virus disease is a severe disease clinically similar to Ebola disease. With no approved treatments or vaccines for MVD, early intervention for those showing symptoms is crucial for improving survival rates.
more
Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to cause epidemics with significant case fatality rates.
Conformément à son mandat, qui prévoit
qu’elle fournisse aux États Membres des orientations à caractère normatif en matière de
politique sanitaire, l’OMS publie une série de
notes de synthèse régulièrement mises à jour
sur les vaccins et les associations vaccinales
contre les ma...ladies ayant une incidence sur la
santé publique internationale. Ces notes de
synthèse portent essentiellement sur l’utilisation des vaccins dans le cadre de programmes
de vaccination à grande échelle.
more
All health and care workers require the knowledge and skills to prevent the transmission of Ebola virus or Marburg virus when providing care for patients. This course provides an overview of the mode of transmission of these viruses, the personal protective equipment required by health and care work...ers and measures to take for rapid identification and isolation as well as managing the environment.
more
La République démocratique du Congo (RDC) mise sur la surveillance communautaire pour mieux riposter à la variole simienne appelée en anglais Mpox. En 2023, plus de 14 000 cas de Mpox ont été détectés. Le pays, avec l’appui de ses partenaires, forme les relais communautaires pour la sensib...ilisation de la population sur l’importance de se rendre rapidement à l’hôpital dès les premiers symptômes.
more
The tab is the result of a preliminary landscape of therapeutics licensed or under development for Mpox
There has been a global outbreak of mpox since 2022; this outbreak has been caused by the strain of mpox virus called Clade 2 and has affected around 116 countries worldwide. The current surge in cases is being driven by the rapid spread of a different strain – Clade 1b – which is predominantly ...affecting countries across the African region, particularly DRC, Burundi, Kenya, Uganda and Rwanda [1]. The guidance in this document applies to both Clades of mpox. WHO publishes a dashboard of updated cases globally here. Different Clades and Sub-Clades of mpox behave slightly differently to each other; WHO is monitoring for any significant differences between the Clades, including transmission routes. This guidance will be updated as more information becomes available on this issue.
more
interim guidance, 25 November 2024